https://www.selleckchem.com/products/vx-561.html
Postpartum depression (PPD) is one of the most common medical complications during and after pregnancy, negatively affecting both mother and child. To demonstrate the efficacy and safety of zuranolone, a neuroactive steroid γ-aminobutyric acid receptor-positive allosteric modulator, in PPD. This phase 3, double-blind, randomized, outpatient, placebo-controlled clinical trial was conducted between January 2017 and December 2018 in 27 enrolling US sites. Participant were women aged 18 to 45 years, 6 months or fewer post partum, with PPD (m
Like
Comment
Share
